Comparison of vildagliptin versus sitagliptin in combination with insulin using continuous glucose monitoring -prospective, randomized, open-label study -

Comparison of vildagliptin versus sitagliptin in combination with insulin using continuous glucose monitoring -prospective, randomized, open-label study - - Continuous glucose profiles with vildagliptin versus sitagliptin in combination with insulin.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010199

Enrollment

Registered

2013-03-31

Start date

2013-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

sitagliptin vildagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with type 2 diabetes using sitagliptin (50mg) and insulin for more than 3 months 2) HbA1c 6.2-8.4% (NGSP) 3) written informed consent

Exclusion criteria

Exclusion criteria: 1) severe hepatic dysfunction, renal dysfunction, heart failure. 2) history of anaphylaxis of sitagliptin or vildagliptin. 3) pregnancy. 4) patients who are inadequate to enter this study due to the other reasons by physician's judgments.

Design outcomes

Primary

Measure	Time frame
MAGE; mean amplitude of glycemic excursions	—

Secondary

Measure	Time frame
1) M-value 2) glucose area under the curve 3) fasting plasma glucose, HbA1c, glycoalbumin, 1.5AG 4) beta cell function 5) several biomarkers 6) body weight, Body Mass Index 7) blood pressure	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026